Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 477-690-9 | CAS number: 874819-71-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity:
LD50 > 2000 mg/kg bw.
Acute dermal toxicity:
LD50 > 2000 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004-10-27 - 2004-08-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- OECD 423 (2001)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species / Strain: rat/WistarCrkWI BR
Rationale:The rat is a suitable rodent species for acute toxicity
studies and is acceptable to regulatory authorities.
Sex:female (nulliparous, non-pregnant)
Supplier:Charles River Wiga GmbH,
D-97320 Sulzfeld
Age at start of acclimatisation: approximately 8 weeks
Acclimatisation: 6 days before randomisation
Randomisation: Animals were assigned to cages according to random numbers one day prior to first administration.
The study room and cages were cleaned and disinfected before the animals arrived. During the study, the room and cages were cleaned at regular intervals. The animals were housed in groups of up to 3 to a cage (Makrolon® Type 3) during acclimatisation. From the randomisation until sacrificing a single animal was housed in a Makrolon® Type 3 cage.
Feed: ALTROMIN 1324. pelleted standard diet (ALTROMIN, D-32791 Lage/Lippe) Batch: 190904/1342 With the exception of overnight fasting before oral administration and until 3 hours after administration food was available ad libitum.
Bedding: ALTROMIN Type S8/15, granulated soft wood bedding Batch: 230604 Water: tap water, ad libitum (municipal supply) Makrolon® bottles, changed daily Environment: air conditioned temperature: 19 - 23 °C relative humidity: 30 - 65% Lighting: artificial light was set to give a cycle of 12 hours light and 12 hours dark; the light phase was from 6.30 a.m. - 6.30 p.m. - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5 % (m/v) solution of Tylose MH 1000 in deionised water
- Details on oral exposure:
- Formulation of Test Item The test item was suspended after crushing with a pestle and mortar to a fine dust shortly before administration in a 0.5 % (m/v) solution of Tylose MH 1000 in deionised water by mixing and continuously mixed by a stirrer during the administration. The homogeneity was proved visually.
All doses are expressed in terms of test item as supplied.
Oral exposure: using a metal catheter and disposable plastic syringes - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 6
- Control animals:
- no
- Details on study design:
- Volume of administration: 1 ml / 100 g body weight Individual doses were adjusted according to the recorded body weight.
Time of administration: single administration Animals 1-3: September 07, 2004; 7.19 - 7.23 a.m.
Animals 4-6: September 08, 2004; 7.13 - 7.15 a.m.
Fasting period: the night before administration and 3 hours after administration. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Number of deaths: 0
- Clinical signs:
- other: Signs of toxicity related to dose levels: Except for a yellow urine on the day of administration and the day thereafter clinical symptoms were not observed during the course of investigation. The body weight gain of the animals was slightly delayed.
- Gross pathology:
- Effects on organs:
No pathological findings were observed. - Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The LD50 (oral, rat) of N-(2-Nitrophenyl)phosphoric triamide is > 2000 mg/kg bw.
- Executive summary:
The acute oral toxicity of N-(2-Nitrophenyl)phosphoric triamide was tested in 6 female Charles River Wistar rats according to OECD guideline 423. The test item was administered at the single dose of 2000 mg/kg body weight (Limit test) by gavage. All animals were examined for mortality, clinical signs and body weight gain. The pathological alterations of organs were examined at the end of a 14-day observation period. None of the animals died during the course of investigation. The LD50 (oral,rat) is > 2000 mg/kg bw.
Except for a yellow urine on the day of administration and the day thereafter clinical sy mptoms were not observed during the course of investigation. The body weight gain of the animals was slightly delayed. No pathological findings were observed.
The LD50 (oral, rat) of N-(2-Nitrophenyl)phosphoric triamide is > 2000 mg/kg bw.
Reference
Hours or days p.a. |
Clinical signs in animal No. |
|||||
1 |
2 |
3 |
4 |
5 |
6 |
|
1 h |
- |
- |
- |
0 |
0 |
0 |
2h |
0 |
0 |
0 |
- |
- |
- |
3 h |
0 |
0 |
0 |
0 |
0 |
0 |
4h |
yellow urine |
yellow urine |
yellow urine |
- |
- |
- |
6h |
- |
- |
- |
yellow urine |
yellow urine |
yellow urine |
1 d |
yellow urine |
yellow urine |
yellow urine |
yellow urine |
yellow urine |
yellow urine |
2 d |
0 |
0 |
0 |
0 |
0 |
0 |
3 d |
0 |
0 |
0 |
0 |
0 |
0 |
4d |
0 |
0 |
0 |
0 |
0 |
0 |
5 d |
0 |
0 |
0 |
0 |
0 |
0 |
6d |
0 |
0 |
0 |
0 |
0 |
0 |
7d |
0 |
0 |
0 |
0 |
0 |
0 |
8 d |
0 |
0 |
0 |
0 |
0 |
0 |
9 d |
0 |
0 |
0 |
0 |
0 |
0 |
10 d |
0 |
0 |
0 |
0 |
0 |
0 |
11 d |
0 |
0 |
0 |
0 |
0 |
0 |
12 d |
0 |
0 |
0 |
0 |
0 |
0 |
13 d |
0 |
0 |
0 |
0 |
0 |
0 |
14 d |
0 |
0 |
0 |
0 |
0 |
0 |
Test group Dose |
Animal No./ Symbol |
Body weight [g| |
Body weight increase [g] |
||||
before administration |
7 days p. a. |
14 days p. a. |
1st week |
2nd week |
total |
||
2000 |
1 |
206 |
236 |
253 |
30 |
17 |
47 |
mg/kg b.w. |
2 |
188 |
213 |
220 |
25 |
7 |
32 |
|
3 |
186 |
212 |
227 |
26 |
15 |
41 |
|
4 |
187 |
218 |
235 |
31 |
17 |
48 |
|
5 |
191 |
206 |
222 |
15 |
16 |
31 |
|
6 |
185 |
207 |
212 |
22 |
5 |
27 |
|
X |
190.5 |
215.3 |
228.2 |
24.8 |
12.8 |
37.7 |
|
± s |
7.9 |
11.0 |
14.4 |
5.8 |
5.4 |
8.9 |
|
n |
6 |
6 |
6 |
6 |
6 |
6 |
p.a. = post applicationem x = mean value + s = standard deviation n = number of values
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The key study is GLP-compliant and has Klimisch score 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004-08-24 - 2004-10-27
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The GLP study was conducted according to an internationally accepted guideline. All study parameters are based on the specific guideline.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Type of coverage:
- occlusive
- Vehicle:
- water
- Details on dermal exposure:
- Approximately 24 hours before administration the fur was removed by shaving from the dorsal area (6x6 cm) of the trunk. Only animals with healthy intact skin were used. 0.2 g / 100 g body weight
Individual doses were adjusted according to the recorded body weight.
The test item was moistened with deionised water, applied to the shaved skin area and covered with a layer of a gaze patch and then with aluminium foil (6.5 x 6.5 cm). This patch was held in contact with the skin by occlusive dressing (Elastoplast, Beiersdorf AG), single administration on September 07, 2004, 9.25 - 9.59 a.m. After 24 hours the patch was removed and the application area was cleaned with water without altering the integrity of the epidermis. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 male and 5 female animals
- Control animals:
- not required
- Details on study design:
- Observations
The animals were observed over a period of 14 days after administration of the test item.
Mortality
Animals were observed for mortality and morbidity continuously on the day of administration and once daily thereafter (in the morning).
Clinical Observations
The animals were monitored for general clinical condition continuously on the day of administration and once daily thereafter (in the morning).
The following signs were given predominant consideration: changes in skin, fur, eyes and mucous membranes; gait and posture; respiratory, circulatory, autonomic and central nervous system; occurrence of secretions and excretions; presence of clonic or tonic movements and stereotypies or bizarre behaviour.
Skin of the Administration Area
Animals were observed for erythema and/or oedema at the skin of the administration area one hour after patch removal and once daily thereafter (in the morning).
Body Weight Gain
Body weights were recorded on the day of administration and on days 7 and 14 thereafter.
Pathology
At the end of the observation period all animals were killed by CO2 inhalation.
All animals were examined externally. The cranial, thoracic and abdominal cavities were then opened and examined macroscopically. - Statistics:
- Body weights and body weight gain:
Calculation of group mean values and standard deviations.
Comparison with historical control data. - Preliminary study:
- None of the animals died after a single dermal administration of 2000 mg/kg b.w. AL(2-NitrophenyI)phosphoric triamide.
Clinical signs were not observed during the observation period.
Except for a slightly yellowish discolouring not any alteration of the skin at the administration area was observed.
The body weight gain of the animals was not affected by the test item. No pathological findings were observed at necropsy. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- none
- Clinical signs:
- other: None of the animals showed alterations of the general state of well-being during the course of investigation.
- Gross pathology:
- There were no macroscopic pathological findings in the animals.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The dermal LD50 of N-(2-Nitrophenyl)phosphoric triamide in the rat is > 2000 mg/kg b.w.
- Executive summary:
Acute dermal toxicity of N-(2 -Nitrophenylphosphoric triamide was tested in 5 male and 5 female Charles River Wistar rats according to OECD guideline 402. The test item was applied at a single dose of 2000 mg/kg body weight to a shaved dorsal area of the trunk of the animals and was then covered with a gauze patch which was held in contact with the skin with an occlusive dressing. Exposure was for 24 hours. Animals were examined for mortality, clinical signs, alterations of the administration area, body weight gain and pathological alterations of organs at the end of a 14-day observation period, None of the animals died during the course of the investigation. The LD50 dermal rat is > 2000 mg/kg b.w. Clinical signs were not observed during the observation period. Except for a slightly yellowish discolouring not any alteration of the skin at the administration area was observed. The body weight gain of the animals was not affected by the test item. No pathological findings were observed at necropsy.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The key study is GLP-compliant and has Klimisch score 1.
Additional information
Acute oral toxicity:
The LD50 (oral, rat) of N-(2-Nitrophenyl)phosphoric triamide was investigated in a GLP-study according to OECD guideline 423. The LD50 is > 2000 mg/kg bw.
Acute dermal toxicity:
The acute dermal toxicity of N-(2-Nitrophenyl)phosphoric triamide was investigated in a GLP-study according to OECD guideline 402. The LD50 is > 2000 mg/kg bw.
Justification for selection of acute toxicity – oral endpoint
Only one study available.
Justification for selection of acute toxicity – dermal endpoint
Only one study available.
Justification for classification or non-classification
Acute oral toxicity:
The respective criteria are not met.
The estimated LD50 of > 2000 mg/kg bw. is above the treshold for hazard category 4 (2000 mg/kg bw).
N-(2-Nitrophenyl)phosphoric triamide
is therefore not classified for acute oral toxicity.
Acute toxicity via the dermal route:
The respective criteria are not met. The estimated LD50 of > 2000 mg/kg bw. is above
the treshold for hazard category 4 (2000 mg/kg bw).
N-(2-Nitrophenyl)phosphoric triamide
is therefore not classified for acute dermal toxicity.
Acute toxicity via the inhalation route:
The dermal route is considered as the major route of exposure for N-(2-Nitrophenyl)posphoric triamide. In addition, as determined by the particle size distribution study, very few particles (4.14 %) are smaller than the respirable particle size of 10 μm. In conclusion further testing on vertebrate animals is not justified, thus the substance will be not classified for acute inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.